13F Holdings
中文EN

ONC BeOne Medicines Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1651308 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY32.9%
TTM net income YoY1,235.6%
TTM EPS YoY1,400.0%
Revenue 3-yr CAGR44.2%
Net income 3-yr CAGR—

Margins

Gross margin89.4%
Operating margin17.8%
Net margin13.9%
FCF margin21.9%
EBITDA margin20.2%

Returns

ROE18.4%
ROA10.5%
ROIC (approx.)158.2%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets41.1%
Debt / equity0.18x
Current ratio3.55x
Interest coverage8.31x

Cash quality & payout

Operating cash flow / net income1.74x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5.34B$3.81B$2.46B$1.42B$1.18B
Cost of revenue———$286.48M$164.91M
Gross profit$4.67B$3.22B$2.08B$1.13B$1.01B
R&D expense$2.15B$1.95B$1.78B$1.64B$1.46B
SG&A expense$2.08B$1.83B$1.51B$1.28B$990.12M
Operating income$447.14M-$568.20M-$1.21B-$1.79B-$1.44B
Interest expense$58.23M$21.80M$4.36M$21.70M$29.26M
Pretax income$416.85M-$533.00M-$825.84M-$1.96B-$1.44B
Income tax$129.92M$111.78M$55.87M$42.78M$19.23M
Net income$286.93M-$644.79M-$881.71M-$2.00B-$1.46B
EBITDA$588.82M-$396.44M-$1.12B-$1.72B-$1.39B
EPS (basic)0.20-0.47-0.65-1.49-1.21
EPS (diluted)0.19-0.47-0.65-1.49-1.21
Weighted avg. shares (diluted)1.47B1.37B1.36B1.34B1.21B
Banking
Net interest income——$74.01M$52.48M-$15.76M
Balance sheet
Cash & equivalents$4.55B$2.64B$3.17B$3.88B$4.38B
Short-term investments——$2.60M$665.25M$2.24B
Receivables$865.08M$676.28M$358.03M$173.17M$483.11M
Inventory$608.23M$494.99M$416.12M$282.35M$242.63M
Current assets$6.23B$3.99B$4.20B$5.21B$7.61B
PP&E, net$1.64B$1.58B$1.32B$845.95M$587.61M
Goodwill———$109,000$109,000
Intangibles$62.70M$51.09M$57.14M$40.62M$46.68M
Total assets$8.19B$5.92B$5.81B$6.38B$8.54B
Current liabilities$1.83B$2.21B$1.81B$1.47B$1.60B
Short-term debt$57.29M$851.53M$688.37M$328.97M$427.56M
Long-term debt$961.91M$166.48M$197.62M$209.15M$202.11M
Total debt$1.02B$1.02B$885.98M$538.12M$629.68M
Total liabilities$3.83B$2.59B$2.27B$2.00B$2.40B
Shareholders' equity$4.36B$3.33B$3.54B$4.38B$6.13B
Net debt-$3.53B-$1.62B-$2.29B-$3.34B-$3.75B
Shares outstanding1.44B1.39B1.36B1.36B1.33B
Cash flow statement
Operating cash flow$1.13B-$140.63M-$1.16B-$1.50B-$1.30B
Capital expenditure$185.84M$492.66M$561.90M$325.43M$262.94M
Free cash flow$941.74M-$633.29M-$1.72B-$1.82B-$1.56B
Investing cash flow-$276.15M-$548.35M$60.00M$1.08B$640.66M
Financing cash flow$1.06B$193.45M$416.48M-$18.97M$3.64B
Depreciation & amortization$141.69M$171.76M$87.67M$66.28M$46.46M
Stock-based compensation$510.86M$441.62M$367.62M$303.16M$240.71M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.